International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
Background - Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of the messenger RNA (mRNA) expression levels of ex...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2022
|
| In: |
Annals of oncology
Year: 2022, Jahrgang: 33, Heft: 1, Pages: 57-66 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2021.09.017 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.annonc.2021.09.017 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753421044963 
|
| Verfasserangaben: | S. Novello, V. Torri, C. Grohe, S. Kurz, M. Serke, T. Wehler, A. Meyer, D. Ladage, M. Geissler, I. Colantonio, C. Cauchi, E. Stoelben, A. Ceribelli, C. Kropf-Sanchen, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, V. Gregorc, R. Chiari, M. Reck, G. Schmid-Bindert, G. Folprecht, F. Griesinger, A. Follador, P. Pedrazzoli, A. Bearz, O. Caffo, N.J. Dickgreber, L. Irtelli, G. Wiest, V. Monica, L. Porcu, C. Manegold and G.V. Scagliotti |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1841086320 | ||
| 003 | DE-627 | ||
| 005 | 20241205134110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230403s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2021.09.017 |2 doi | |
| 035 | |a (DE-627)1841086320 | ||
| 035 | |a (DE-599)KXP1841086320 | ||
| 035 | |a (OCoLC)1475285491 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Novello, Silvia |e VerfasserIn |0 (DE-588)1339521407 |0 (DE-627)1899154280 |4 aut | |
| 245 | 1 | 0 | |a International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer |c S. Novello, V. Torri, C. Grohe, S. Kurz, M. Serke, T. Wehler, A. Meyer, D. Ladage, M. Geissler, I. Colantonio, C. Cauchi, E. Stoelben, A. Ceribelli, C. Kropf-Sanchen, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, V. Gregorc, R. Chiari, M. Reck, G. Schmid-Bindert, G. Folprecht, F. Griesinger, A. Follador, P. Pedrazzoli, A. Bearz, O. Caffo, N.J. Dickgreber, L. Irtelli, G. Wiest, V. Monica, L. Porcu, C. Manegold and G.V. Scagliotti |
| 264 | 1 | |c January 2022 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 5. Oktober 2021, Artikelversion: 16. Dezember 2021 | ||
| 500 | |a Gesehen am 20.08.2024 | ||
| 520 | |a Background - Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of the messenger RNA (mRNA) expression levels of excision repair cross complementation group 1 (ERCC1) and thymidylate synthase (TS) as assessed in resected tumor. - Patients and methods - Seven hundred and seventy-three completely resected stage II-III NSCLC patients were enrolled and randomly assigned in each of the four genomic subgroups to investigator’s choice of platinum-based chemotherapy (C, n = 389) or tailored chemotherapy (T, n = 384). All anticancer drugs were administered according to standard doses and schedules. Stratification factors included stage and smoking status. The primary endpoint of the study was overall survival (OS). - Results - Six hundred and ninety patients were included in the primary analysis. At a median follow-up of 45.9 months, 85 (24.6%) and 70 (20.3%) patients died in arms C and T, respectively. Five-year survival for patients in arms C and T was of 65.4% (95% CI (confidence interval): 58.5% to 71.4%) and 72.9% (95% CI: 66.5% to 78.3%), respectively. The estimated hazard ratio (HR) was 0.77 (95% CI: 0.56-1.06, P value: 0.109) for arm T versus arm C. HR for recurrence-free survival was 0.89 (95% CI: 0.69-1.14, P value: 0.341) for arm T versus arm C. Grade 3-5 toxicities were more frequently reported in arm C than in arm T. - Conclusion - In completely resected stage II-III NSCLC tailoring adjuvant chemotherapy conferred a non-statistically significant trend for OS favoring the T arm. In terms of safety, the T arm was associated with better efficacy/toxicity ratio related to the different therapeutic choices in the experimental arm. | ||
| 650 | 4 | |a adjuvant chemotherapy | |
| 650 | 4 | |a excision repair cross-complementation 1 | |
| 650 | 4 | |a messenger RNA | |
| 650 | 4 | |a non-small-cell lung cancer | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a thymidylate synthase | |
| 700 | 1 | |a Torri, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grohé, Christian |e VerfasserIn |0 (DE-588)1222446383 |0 (DE-627)1741490987 |4 aut | |
| 700 | 1 | |a Kurz, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Serke, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wehler, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meyer, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ladage, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geissler, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Colantonio, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cauchi, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stoelben, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ceribelli, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kropf-Sanchen, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Valmadre, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borra, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schena, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Morabito, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Santo, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gregorc, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chiari, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reck, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmid-Bindert, Gerald |d 1969- |e VerfasserIn |0 (DE-588)121300129 |0 (DE-627)081214170 |0 (DE-576)292636024 |4 aut | |
| 700 | 1 | |a Folprecht, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Griesinger, Frank |e VerfasserIn |0 (DE-588)1080408916 |0 (DE-627)844436305 |0 (DE-576)453541747 |4 aut | |
| 700 | 1 | |a Follador, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pedrazzoli, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bearz, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Caffo, O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dickgreber, N. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Irtelli, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wiest, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Monica, V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Porcu, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manegold, Christian |d 1946-2022 |e VerfasserIn |0 (DE-588)108614913 |0 (DE-627)490287360 |0 (DE-576)289617200 |4 aut | |
| 700 | 1 | |a Scagliotti, G. V. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 33(2022), 1 vom: Jan., Seite 57-66 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:1 |g month:01 |g pages:57-66 |g extent:10 |a International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer |
| 787 | 0 | 8 | |i Errata |a Novello, Silvia |t Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer” |d 2022 |w (DE-627)1841086177 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2021.09.017 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753421044963 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240820 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 108614913 |a Manegold, Christian |m 108614913:Manegold, Christian |d 60000 |e 60000PM108614913 |k 0/60000/ |p 35 |y j | ||
| 998 | |g 121300129 |a Schmid-Bindert, Gerald |m 121300129:Schmid-Bindert, Gerald |d 60000 |e 60000PS121300129 |k 0/60000/ |p 23 | ||
| 999 | |a KXP-PPN1841086320 |e 4569080758 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer","title":"International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer"}],"recId":"1841086320","language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["S. Novello, V. Torri, C. Grohe, S. Kurz, M. Serke, T. Wehler, A. Meyer, D. Ladage, M. Geissler, I. Colantonio, C. Cauchi, E. Stoelben, A. Ceribelli, C. Kropf-Sanchen, G. Valmadre, G. Borra, M. Schena, A. Morabito, A. Santo, V. Gregorc, R. Chiari, M. Reck, G. Schmid-Bindert, G. Folprecht, F. Griesinger, A. Follador, P. Pedrazzoli, A. Bearz, O. Caffo, N.J. Dickgreber, L. Irtelli, G. Wiest, V. Monica, L. Porcu, C. Manegold and G.V. Scagliotti"]},"person":[{"roleDisplay":"VerfasserIn","family":"Novello","given":"Silvia","display":"Novello, Silvia","role":"aut"},{"given":"V.","display":"Torri, V.","role":"aut","family":"Torri","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Grohé","display":"Grohé, Christian","role":"aut","given":"Christian"},{"roleDisplay":"VerfasserIn","family":"Kurz","given":"S.","display":"Kurz, S.","role":"aut"},{"display":"Serke, M.","role":"aut","given":"M.","family":"Serke","roleDisplay":"VerfasserIn"},{"family":"Wehler","roleDisplay":"VerfasserIn","role":"aut","display":"Wehler, T.","given":"T."},{"given":"A.","role":"aut","display":"Meyer, A.","roleDisplay":"VerfasserIn","family":"Meyer"},{"family":"Ladage","roleDisplay":"VerfasserIn","given":"D.","display":"Ladage, D.","role":"aut"},{"family":"Geissler","roleDisplay":"VerfasserIn","display":"Geissler, M.","role":"aut","given":"M."},{"roleDisplay":"VerfasserIn","family":"Colantonio","given":"I.","role":"aut","display":"Colantonio, I."},{"family":"Cauchi","roleDisplay":"VerfasserIn","display":"Cauchi, C.","role":"aut","given":"C."},{"role":"aut","display":"Stoelben, E.","given":"E.","family":"Stoelben","roleDisplay":"VerfasserIn"},{"display":"Ceribelli, A.","role":"aut","given":"A.","family":"Ceribelli","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Kropf-Sanchen","display":"Kropf-Sanchen, C.","role":"aut","given":"C."},{"given":"G.","display":"Valmadre, G.","role":"aut","roleDisplay":"VerfasserIn","family":"Valmadre"},{"given":"G.","role":"aut","display":"Borra, G.","family":"Borra","roleDisplay":"VerfasserIn"},{"family":"Schena","roleDisplay":"VerfasserIn","role":"aut","display":"Schena, M.","given":"M."},{"role":"aut","display":"Morabito, A.","given":"A.","family":"Morabito","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Santo","given":"A.","role":"aut","display":"Santo, A."},{"roleDisplay":"VerfasserIn","family":"Gregorc","role":"aut","display":"Gregorc, V.","given":"V."},{"family":"Chiari","roleDisplay":"VerfasserIn","given":"R.","display":"Chiari, R.","role":"aut"},{"given":"M.","role":"aut","display":"Reck, M.","family":"Reck","roleDisplay":"VerfasserIn"},{"given":"Gerald","role":"aut","display":"Schmid-Bindert, Gerald","roleDisplay":"VerfasserIn","family":"Schmid-Bindert"},{"roleDisplay":"VerfasserIn","family":"Folprecht","display":"Folprecht, G.","role":"aut","given":"G."},{"role":"aut","display":"Griesinger, Frank","given":"Frank","family":"Griesinger","roleDisplay":"VerfasserIn"},{"family":"Follador","roleDisplay":"VerfasserIn","display":"Follador, A.","role":"aut","given":"A."},{"given":"P.","display":"Pedrazzoli, P.","role":"aut","family":"Pedrazzoli","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Bearz","given":"A.","display":"Bearz, A.","role":"aut"},{"display":"Caffo, O.","role":"aut","given":"O.","family":"Caffo","roleDisplay":"VerfasserIn"},{"display":"Dickgreber, N. J.","role":"aut","given":"N. J.","roleDisplay":"VerfasserIn","family":"Dickgreber"},{"roleDisplay":"VerfasserIn","family":"Irtelli","given":"L.","display":"Irtelli, L.","role":"aut"},{"role":"aut","display":"Wiest, G.","given":"G.","family":"Wiest","roleDisplay":"VerfasserIn"},{"family":"Monica","roleDisplay":"VerfasserIn","given":"V.","display":"Monica, V.","role":"aut"},{"family":"Porcu","roleDisplay":"VerfasserIn","role":"aut","display":"Porcu, L.","given":"L."},{"given":"Christian","display":"Manegold, Christian","role":"aut","roleDisplay":"VerfasserIn","family":"Manegold"},{"given":"G. V.","display":"Scagliotti, G. V.","role":"aut","roleDisplay":"VerfasserIn","family":"Scagliotti"}],"note":["Online verfügbar: 5. Oktober 2021, Artikelversion: 16. Dezember 2021","Gesehen am 20.08.2024"],"physDesc":[{"extent":"10 S."}],"relHost":[{"part":{"issue":"1","volume":"33","extent":"10","text":"33(2022), 1 vom: Jan., Seite 57-66","pages":"57-66","year":"2022"},"pubHistory":["1.1990 -"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"European Society for Medical Oncology","role":"isb"}],"recId":"320428796","title":[{"title":"Annals of oncology","title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"disp":"International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerAnnals of oncology","origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedKey":"1990","dateIssuedDisp":"1990-"}],"id":{"zdb":["2003498-2"],"issn":["1569-8041"],"eki":["320428796"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"]}],"id":{"eki":["1841086320"],"doi":["10.1016/j.annonc.2021.09.017"]},"origin":[{"dateIssuedDisp":"January 2022","dateIssuedKey":"2022"}]} | ||
| SRT | |a NOVELLOSILINTERNATIO2022 | ||